054670.Kq
The company operates in the pharmaceuticals industry, focusing on the development, production, and sale of prescription drugs and related healthcare products.
Business. The company operates in the pharmaceuticals industry, focusing on the development, production, and sale of prescription drugs and related healthcare products.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
The company operates in the pharmaceuticals industry, focusing on the development, production, and sale of prescription drugs and related healthcare products.
The company maintains a debt-to-equity ratio of 0.71, indicating a moderate level of leverage relative to its equity base. Its current ratio of 1.55 suggests that it has sufficient short-term assets to cover its short-term liabilities, though its liquidity position is assessed as medium due to negative net cash after subtracting total debt. The company's free cash flow is negative at -32.9 billion KRW, primarily driven by capital expenditures of -51.1 billion KRW, which may signal ongoing investment in infrastructure or expansion.
Profitability metrics show a return on equity (ROE) of 10.9% and a return on assets (ROA) of 5.63%, both of which are key indicators of the company's efficiency in generating returns from its equity and total assets. These figures suggest that the company is performing above the industry median in terms of ROE, though the ROA is in line with the industry average.
The company's revenue is concentrated in a single business segment, with no disclosed geographic breakdown. This lack of diversification may expose the company to higher risk if demand for its products fluctuates in its primary market. The absence of segment or geographic data limits the ability to assess the company's exposure to different markets or product lines.
Looking ahead, the company is expected to maintain a stable revenue trajectory, with no significant growth or decline projected in the next fiscal year. The company's capital expenditures are expected to remain high, which may impact its free cash flow and liquidity in the near term. The company's operating cash flow of 5.06 billion KRW is relatively modest compared to its capital outlays, which may necessitate continued reliance on debt or equity financing to fund its operations.
The company's risk profile is characterized by a medium liquidity risk and a low dilution risk. The key risk flag is the negative net cash position after subtracting total debt, which could limit the company's ability to fund operations without external financing. The dilution risk is low, as the number of shares outstanding has not changed between basic and diluted shares, indicating no imminent threat of share dilution.
Recent filings and transcripts do not indicate any material events or strategic shifts that would significantly alter the company's financial or operational outlook. The company's financial performance appears to be in line with its historical trends, with no major disruptions or opportunities identified in the latest disclosures.
- The company has a moderate debt-to-equity ratio of 0.71, indicating a balanced capital structure.
- The company's ROE of 10.9% is strong, suggesting efficient use of equity to generate returns.
- Free cash flow is negative at -32.9 billion KRW, primarily due to high capital expenditures.
- The company's liquidity is assessed as medium, with a current ratio of 1.55 but negative net cash after debt.
- The company's risk profile is characterized by medium liquidity risk and low dilution risk.
- No significant growth or decline in revenue is expected in the next fiscal year.
Bull / Bear case
analysis pipelineIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Capex To Revenuecapital_expenditure / revenue
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- 054670.KQ Market data — financials · 2026-05-26